CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Myeloablative Chemotherapy +1 moreprocedure
Likely dose
Carboplatin and thiotepa at high doses (specific doses not stated in eligibility or interventions section)AI-extracted
Key inclusion· 6
  • ✓Age ≤21 years
  • ✓Histologically-confirmed eligible cancer types: Wilms tumor, liver cancer, recurrent brain tumor of childhood, nasopharyngeal carcinoma, fibrosarcoma, desmoplastic small round cell tumor, germ cell tumor, or other small round cell tumor
  • ✓Metastatic disease with <25% cure rate with conventional treatment, OR progressed after prior chemotherapy with <25% salvage rate with non-myeloablative therapies
  • ✓Complete or good partial remission, or chemosensitive disease (>50% decrease in at least one measurable tumor parameter from prior chemotherapy without progressive disease)
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00141765
NCT00141765Phase 2Completed
CompareCT.gov

Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers

University of Michigan Rogel Cancer Center·interventional·Posted Sep 1, 2005·Updated Jun 20, 2014

In Brief

A Phase 2 clinical trial evaluating Myeloablative Chemotherapy and Stem Cell Rescue for Wilms Tumor and 4 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer, Brain Tumor, Recurrent
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 1, 2005
Enrollment StartJan 1, 1997
Primary CompletionDec 1, 2008
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11.9 yearsPosted 20.8 years ago

Interventions

Myeloablative Chemotherapyprocedure

High dose chemotherapy (carboplatin and thiotepa) transplant rescue

Stem Cell Rescueprocedure

autologous stem cell transplantation